银屑病关节炎药物治疗:2019年EULAR推荐更新的系统文献研究
该研究系统检索2015-2018年银屑病关节炎(PsA)所有改善病情抗风湿药(DMARDs)的文献,纳入56篇出版物(疗效33篇、安全性23篇)。多种药物对照安慰剂显示疗效,但疗效因PsA表现而异;未发现新的安全性信号,但监管机构基于其他研究对JAK抑制剂发出静脉血栓栓塞事件风险警告。该综述为2019年EULAR更新版PsA管理推荐提供了依据。
要点
- 多种DMARDs(含TNF抑制剂、IL-17A抑制剂、IL-23-p19抑制剂等)在PsA中对照安慰剂显示疗效。
- 疗效因PsA的不同表现而异,需结合安全性综合考量。
- 未发现新的安全性信号,但JAK抑制剂有静脉血栓栓塞事件风险警告。
核心结论
- PsA可用药物众多且对照安慰剂显示疗效,疗效因表现而异,安全性须纳入考量。
研究设计与样本
- 系统文献研究检索Medline、Embase和Cochrane Library中2015-2018年所有DMARDs治疗PsA的文献。
- 疗效评估基于随机对照试验,安全性分析纳入队列研究、病例对照研究和长期延伸研究。
- 共分析56篇出版物,其中疗效研究33篇、安全性研究23篇。
主要发现
- 文献涉及TNF抑制剂(戈利木单抗、依那西普及生物类似药,n=6)、IL-17A抑制剂(ixekizumab、secukinumab,n=10)、IL-23-p19抑制剂(guselkumab、risankizumab,n=2)、clazakizumab(IL-6抑制剂)、abatacept(CD80/86抑制剂)和ABT-122(抗TNF/IL-17A)。
- 一项研究在附着点疾病患者中比较了ustekinumab(IL-12/23抑制剂)与TNF抑制剂治疗。
- 三篇文章探讨了DMARD减量;靶向合成DMARDs试验研究了apremilast(磷酸二酯酶-4抑制剂)和JAK抑制剂(tofacitinib、filgotinib)。
- 生物类似药与原研生物药比较显示非劣效性。
- 安全性在13项长期延伸研究、9项队列研究和1项病例对照研究中评估,涉及恶性肿瘤、感染、输注反应、多发性硬化、主要心血管事件及疫苗接种的疗效与安全性。
关键数值与推荐
- 未发现新的安全性信号,但监管机构基于其他研究对JAK抑制剂使用中静脉血栓栓塞事件(包括肺栓塞)风险发出警告。
临床怎么用
- 临床选择DMARDs时应考虑PsA的具体表现,并兼顾安全性。
- 使用JAK抑制剂时需警惕静脉血栓栓塞事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To perform an update of a review of the efficacy and safety of disease-modifying antirheumatic drugs (DMARDs) in psoriatic arthritis (PsA). METHODS: This is a systematic literature research of 2015-2018 publications on all DMARDs in patients with PsA, searching Medline, Embase and the Cochrane Library. Efficacy was assessed in randomised controlled trials. For safety, cohort studies, case-control studies and long-term extensions (LTEs) were analysed. RESULTS: 56 publications (efficacy: n=33; safety n=23) were analysed. The articles were on tumour necrosis factor (TNF) inhibitors (n=6; golimumab, etanercept and biosimilars), interleukin (IL)-17A inhibitors (n=10; ixekizumab, secukinumab), IL-23-p19 inhibitors (n=2; guselkumab, risankizumab), clazakizumab (IL-6 inhibitor), abatacept (CD80/86 inhibitor) and ABT-122 (anti-TNF/IL-17A), respectively. One study compared ustekinumab (IL-12/23i) with TNF inhibitor therapy in patients with entheseal disease. Three articles investigated DMARD tapering. Trials on targeted synthetic DMARDs investigated apremilast (phosphodiesterase-4 inhibitor) and Janus kinase inhibitors (JAKi; tofacitinib, filgotinib). Biosimilar comparison with bio-originator showed non-inferiority. Safety was evaluated in 13 LTEs, 9 cohort studies and 1 case-control study investigating malignancies, infections, infusion reactions, multiple sclerosis and major cardiovascular events, as well as efficacy and safety of vaccination. No new safety signals were identified; however, warnings on the risk of venous thromboembolic events including pulmonary embolism when using JAKi were issued by regulators based on other studies. CONCLUSION: Many drugs in PsA are available and have demonstrated efficacy against placebo. Efficacy varies across PsA manifestations. Safety must also be taken into account. This review informed the development of the European League Against Rheumatism 2019 updated PsA management recommendations.
引用
- Kerschbaumer A, Smolen JS, Dougados M, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2020. PMID: 32381564. doi:10.1136/annrheumdis-2020-217163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。